Droloxifene

DB15641

small molecule investigational

Deskripsi

Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity give it theoretical advantages over tamoxifen in the treatment of human breast cancer. Short-term toxicity was generally mild, and similar to that seen with other antiestrogens. Droloxifene appears active and tolerable. It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required. Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because it can prevent estrogen deficiency-induced bone loss without causing uterine hypertrophy. Droloxifene may have an effect on bone and breast tissue because it induces apoptosis. Droloxifene has an anti-implantation effect in rats, and the effect appears to be not completely due to its anti-estrogenic activity.^L34184

Struktur Molekul 2D

Berat 387.523

Wujud -

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

39 Data

Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Droloxifene.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Droloxifene.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Droloxifene.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Droloxifene.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Lidocaine.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Ropivacaine.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Bupivacaine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Cinchocaine.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Dyclonine.
Procaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Procaine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Prilocaine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Proparacaine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Meloxicam.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Oxybuprocaine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Cocaine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Mepivacaine.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Levobupivacaine.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Diphenhydramine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Benzocaine.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Chloroprocaine.
Phenol	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Phenol.
Tetrodotoxin	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Tetrodotoxin.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Benzyl alcohol.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Capsaicin.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Etidocaine.
Articaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Articaine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Tetracaine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Propoxycaine.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Pramocaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Butamben.
Butacaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Butacaine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Oxetacaine.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Ethyl chloride.
Butanilicaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Butanilicaine.
Metabutethamine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Metabutethamine.
Quinisocaine	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Quinisocaine.
Nelarabine	The risk or severity of adverse effects can be increased when Nelarabine is combined with Droloxifene.
Ambroxol	The risk or severity of methemoglobinemia can be increased when Droloxifene is combined with Ambroxol.
Etrasimod	The risk or severity of immunosuppression can be increased when Droloxifene is combined with Etrasimod.

Target Protein

Estrogen receptor ESR1

Referensi & Sumber

Link

DROLOXIFENE: Inxight Drugs

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.